Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19

FRIDAY, Feb. 4, 2022 (HealthDay News) -- For hospitalized COVID-19 patients, bleeding events are more common after receiving full-dose anticoagulation, according to a study published online Dec. 27 in Hospital Pharmacy.
Maya R. Chilbert, Pharm.D., from the University at Buffalo in New York, and colleagues conducted a multicenter, retrospective cohort study to compare the safety and effectiveness of thromboprophylaxis strategies at two institutions for hospitalized COVID-19 patients. Regimen A included a higher-than-standard thromboprophylaxis dosage, while regimen B was D-dimer-driven, with full-dose anticoagulation for any D-dimer 3 mcg/mL or greater and prophylactic for less than 3 mcg/mL. The analysis included 153 patients: 64 and 89 receiving regimens A and B, respectively.
The researchers found seven thrombotic events (4.6 percent): three and four in regimens A and B, respectively (4.7 versus 4.5 percent). Two and 12 patients in regimens A and B had a bleeding event, respectively (3.1 versus 13.5 percent); in each group, half the events were major. All patients who bled were receiving mechanical ventilation; 12 of 14 received full-dose anticoagulation. Readmission with a pulmonary embolism occurred in one patient from regimen A.
"Caution should be used in mechanically ventilated patients with COVID-19 when selecting a regimen to treat blood clots, and the decision to use full-dose blood thinners should be based on a compelling indication rather than lab markers alone," Chilbert said in a statement.
Abstract/Full Text (subscription or payment may be required)
Related Posts
EE. UU. reabre las fronteras a los viajeros extranjeros vacunados
LUNES, 8 de noviembre de 2021 (HealthDay News) -- Por primera vez en más de 18...
Un implante puede alertar con semanas de anticipación que un órgano trasplantado será rechazado
VIERNES, 8 de septiembre de 2023 (Noticias de HealthDay) -- Recibir un...
Cediranib Shows Promise for Differentiated Thyroid Cancer
TUESDAY, Sept. 19, 2023 (HealthDay News) -- The multitargeted tyrosine kinase...
White House’s Top Science Advisor Resigns After Probe Into ‘Disrespectful’ Behavior
TUESDAY, Feb. 8, 2022 (HealthDay News) -- Dr. Eric Lander, the director of the...